Sign In
to Vote &
Create Storyboards.
 
Four-year data from the Zilver® PTX® Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease from Cook Medical presented at the 2013 Vascular Interventional Advances (VIVA) meeting demonstrates 75 percent primary patency in the superficial femoral artery (SFA) at four years for patients treated with Cook Medical's paclitaxel-eluting stent. This compares to 57.9 percent patency for patients with provisional bare metal stent placement in the study...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard